CM
BIO icon

Caption Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Caption Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,324
Closed -$1.4M – 1218
2023
Q4 		$1.4M Buy
+4,324
New +$1.36M 0.02% 722

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Caption Management's BIO Position: Q1 2024 in Review

Caption Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 4,324 shares — an estimated $1.4M sold.

Caption Management first reported a position in BIO in Q4 2023 and held it in 1 quarter. The position peaked at $1.4M in Q4 2023. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Caption Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
  • Caption Management sold 4,324 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $1.4M.
  • Caption Management first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 1 quarter.
  • Caption Management's Bio-Rad Laboratories Class A position peaked at $1.4M in Q4 2023.
  • 466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.